| 2022-03-03 | -25.4% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2021-08-10 | -22.8% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2023-06-15 | -20.4% | legal | SEC EDGAR | STXS 8-K: 8.01 and (SEC Filing) |
| 2025-11-12 | -19.8% | earnings | Seeking Alpha | Stereotaxis shares drop after Q3 loss widens, GenesisX limited launch underway |
| 2025-11-12 | -19.8% | earnings | Seeking Alpha | Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript |
| 2025-11-12 | -19.8% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-11-12 | -19.8% | earnings | Seeking Alpha | Stereotaxis shares drop after Q3 loss widens, GenesisX limited launch underway (STXS:NYSE) - Seeking Alpha |
| 2024-11-12 | +19.2% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-08-08 | +15.4% | earnings | Seeking Alpha | Stereotaxis reiterates double-digit revenue growth outlook for 2025 as new catheter launches drive commercial momentum |
| 2025-08-08 | +15.4% | earnings | Seeking Alpha | Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript |
| 2022-08-09 | -15.3% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2023-11-09 | -13.8% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-11-11 | -13.2% | earnings | Seeking Alpha | Stereotaxis GAAP EPS of -$0.07 misses by $0.01, revenue of $7.46M misses by $0.92M |
| 2023-03-03 | -12.4% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2022-05-10 | -11.1% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-08-07 | +10.4% | earnings | Seeking Alpha | Stereotaxis GAAP EPS of -$0.05 beats by $0.02, revenue of $8.8M beats by $0.67M |
| 2025-08-07 | +10.4% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-02-28 | -10.4% | earnings | Seeking Alpha | Stereotaxis Q4 2024 Earnings Preview |
| 2026-01-06 | +9.9% | legal | Stock Titan | FDA approves MAGiC robotic heart catheter to treat complex arrhythmias - Stock Titan |
| 2023-08-10 | +9.9% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-03-03 | -9.7% | earnings | Seeking Alpha | Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript |
| 2025-03-03 | -9.7% | earnings | Seeking Alpha | Stereotaxis misses Q4 top-line and bottom-line estimates; initiates FY25 outlook |
| 2025-03-03 | -9.7% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-03-03 | -9.7% | earnings | Stock Titan | Can Stereotaxis Turn Q4 Momentum Into Sustained Growth After Flat 2024 Results? - Stock Titan |
| 2024-03-04 | -8.9% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-05-09 | -7.3% | earnings | Seeking Alpha | Stereotaxis Q1 2025 Earnings Preview |
| 2024-12-02 | -7.3% | expansion | Seeking Alpha | Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025 |
| 2022-08-26 | -6.9% | analyst | TradingView | STXS Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-03-10 | -6.5% | earnings | Seeking Alpha | Stereotaxis targets $40M+ annual revenue with manufacturing ramp and product innovation in 2026 |
| 2026-03-10 | -6.5% | earnings | Seeking Alpha | Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript |
| 2023-08-19 | +6.4% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Stereotaxis (STXS) - Zacks Investment Research |
| 2021-05-10 | +6.4% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | +6.3% | executive | Stock Titan | Stereotaxis (STXS) CFO awarded 40,000 options at $1.87 strike price - Stock Titan |
| 2024-08-12 | +5.8% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2024-05-23 | -5.2% | M&A | Seeking Alpha | Stereotaxis Makes A Strategic Acquisition Bolstering Its Future (NYSE:STXS) - Seeking Alpha |
| 2026-03-06 | -5.0% | earnings | Seeking Alpha | Stereotaxis Q4 2025 Earnings Preview |
| 2025-05-12 | -4.9% | earnings | Seeking Alpha | Stereotaxis, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-05-12 | -4.9% | earnings | Seeking Alpha | Stereotaxis reiterates double-digit revenue growth outlook for 2025 as recurring revenue and MAGiC adoption ramp |
| 2025-05-12 | -4.9% | earnings | Seeking Alpha | Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript |
| 2025-05-12 | -4.9% | earnings | Seeking Alpha | Stereotaxis GAAP EPS of -$0.07 beats by $0.01, revenue of $7.5M beats by $0.62M |
| 2025-05-12 | -4.9% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-05-12 | -4.9% | news | GuruFocus | Stereotaxis (STXS) Projects Robust Growth for 2025 | STXS Stock News - GuruFocus |
| 2025-02-14 | -4.7% | earnings | Seeking Alpha | Stock Market Sleeps On Stereotaxis MAGiC CE Mark |
| 2026-03-09 | -4.6% | earnings | Seeking Alpha | Stereotaxis GAAP EPS of -$0.06 beats by $0.01, revenue of $8.64M misses by $0.6M |
| 2026-03-09 | -4.6% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2026-03-09 | -4.6% | earnings | Yahoo Finance | Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2026-03-09 | -4.6% | earnings | Stock Titan | Surgical robotics firm Stereotaxis aims to top $40M revenue in 2026 - Stock Titan |
| 2024-05-13 | -4.6% | legal | SEC EDGAR | STXS 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-03-04 | -4.5% | news | Intellectia AI | STXS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2025-09-22 | +4.3% | news | Seeking Alpha | Stereotaxis At Inflection Point: Why I Choose To Hold |
| 2025-09-22 | +4.3% | news | Seeking Alpha | Stereotaxis At Inflection Point: Why I Choose To HOLD (NYSE:STXS) - Seeking Alpha |
| 2026-01-27 | -4.2% | news | Finimize | Stereotaxis Bets On New Catheters To Turn Its Niche Into Growth - Finimize |
| 2024-03-09 | -4.0% | legal | Seeking Alpha | Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months (NYSE:STXS) - Seeking Alpha |
| 2025-07-17 | -3.5% | news | Seeking Alpha | Stereotaxis announces $12.5 million offering; shares slip over 7% |
| 2025-07-17 | -3.5% | legal | SEC EDGAR | STXS 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-07-17 | -3.5% | legal | SEC EDGAR | STXS 8-K: 2.02 and 8.01 (SEC Filing) |
| 2026-02-09 | +3.2% | news | Stock Titan | First German heart center turns to robots to cut radiation - Stock Titan |
| 2024-03-02 | -3.2% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-11-10 | +3.0% | earnings | Seeking Alpha | Stereotaxis Q3 2025 Earnings Preview |
| 2025-08-06 | -2.9% | earnings | Seeking Alpha | Stereotaxis Q2 2025 Earnings Preview |
| 2026-04-17 | -2.5% | M&A | Zacks | STXS to Acquire Robocath to Lead in Endovascular Robotics Market |
| 2026-04-17 | -2.5% | M&A | TradingView | STXS to Acquire Robocath to Lead in Endovascular Robotics Market - TradingView |
| 2021-07-26 | -2.4% | legal | SEC EDGAR | STXS 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-21 | -2.4% | news | GlobeNewswire | Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026 |
| 2026-04-21 | -2.4% | earnings | Stock Titan | After the close, Stereotaxis will break down Q1 results on May 12 - Stock Titan |
| 2025-08-29 | -2.2% | legal | SEC EDGAR | STXS 8-K: 1.01 and (SEC Filing) |
| 2025-01-13 | -2.2% | news | Yahoo Finance | Why Stereotaxis (STXS) Is Among the Cheap Robotics Stocks to Invest In Now? - Yahoo Finance |
| 2021-11-12 | -2.1% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2026-04-15 | -2.0% | M&A | MT Newswires | Stereotaxis to Acquire Robocath in Deal Worth Up to $45 Million |
| 2026-04-15 | -2.0% | M&A | GlobeNewswire | Stereotaxis Announces Definitive Agreement to Acquire Robocath |
| 2026-04-15 | -2.0% | news | MedTech Dive | Stereotaxis to buy Robocath for up to $45M |
| 2026-04-15 | -2.0% | news | Seeking Alpha | Stereotaxis, Inc. (STXS) M&A Call Transcript |
| 2026-04-15 | -2.0% | M&A | Seeking Alpha | Stereotaxis to acquire Robocath for $20M upfront |
| 2026-04-15 | -2.0% | legal | SEC EDGAR | STXS 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2026-04-15 | -2.0% | M&A | Stock Titan | Stereotaxis (STXS) plans Robocath acquisition with $20M upfront and $25M earnout - Stock Titan |
| 2026-04-15 | -2.0% | M&A | Stock Titan | Europe’s only commercial coronary robot joins Stereotaxis in $45M deal - Stock Titan |
| 2025-07-06 | -2.0% | earnings | Seeking Alpha | Stereotaxis: Recurring Revenue Inflection |
| 2025-07-06 | -2.0% | earnings | Seeking Alpha | Stereotaxis Stock: Recurring Revenue Inflection (NYSE:STXS) - Seeking Alpha |
| 2026-03-22 | +1.7% | legal | Stock Titan | [EFFECT] Stereotaxis, Inc. SEC Filing - Stock Titan |
| 2023-05-09 | +1.7% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2026-04-06 | -1.6% | legal | MT Newswires | Stereotaxis Gets US FDA Clearance for Synchrony Imaging Technology |
| 2026-04-06 | -1.6% | expansion | Seeking Alpha | Stereotaxis wins FDA clearance for Synchrony system, launches platform |
| 2026-04-06 | -1.6% | legal | Stock Titan | Stereotaxis gets FDA clearance for cath lab system, targets $3M - Stock Titan |
| 2026-04-06 | -1.6% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | Can Stereotaxis (STXS) Stock Beat Estimates | Price at $1.96, Up 4.55% - Expert Verified Trades - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-04-22 | +1.5% | news | GlobeNewswire | Stereotaxis Announces First MAGiC Procedures in the United States |
| 2026-04-22 | +1.5% | news | Stock Titan | First US patients get new catheter for hard-to-treat heart rhythm - Stock Titan |
| 2025-12-16 | +1.4% | analyst | eToro | Stereotaxis Inc (STXS) Stock Price, News & Analyst Forecast - eToro |
| 2026-03-13 | +1.1% | news | Seeking Alpha | Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks |
| 2026-03-13 | +1.1% | news | Seeking Alpha | Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks (NYSE:STXS) - Seeking Alpha |
| 2024-08-02 | -1.1% | legal | SEC EDGAR | STXS 8-K: 3.02 and 8.01 (SEC Filing) |
| 2024-07-18 | -1.0% | legal | SEC EDGAR | STXS 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-23 | -0.9% | news | Zacks | Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval |
| 2026-04-23 | -0.9% | news | TradingView | Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval - TradingView |
| 2025-12-15 | +0.8% | earnings | MarketBeat | 3 Underrated Robotics Stocks Poised for Huge Gains - MarketBeat |
| 2024-05-16 | +0.5% | legal | SEC EDGAR | STXS 8-K: 1.01, 3.02and5.07 (SEC Filing) |
| 2026-04-16 | -0.5% | M&A | Medical Device Network | Stereotaxis to acquire Robocath for up to $45m |
| 2021-08-27 | +0.3% | legal | SEC EDGAR | STXS 8-K: 8.01 and (SEC Filing) |
| 2022-11-10 | -0.1% | legal | SEC EDGAR | STXS 8-K: 2.02 and (SEC Filing) |
| 2025-03-07 | -0.1% | legal | Seeking Alpha | Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn |
| 2026-04-07 | +0.1% | legal | Zacks | STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery |
| 2026-04-07 | +0.1% | legal | bitget.com | STXS Rises After FDA Approval for Synchrony System, Broadens Digital Surgery Portfolio - bitget.com |
| 2026-04-07 | +0.1% | legal | TradingView | STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery - TradingView |
| 2026-04-04 | +0.1% | news | Intellectia AI | STXS Technical Analysis & Stock Price Forecast - Intellectia AI |
| 2026-04-03 | +0.1% | news | Stock Titan | Stereotaxis (NYSE: STXS) details 2026 meeting, director elections and say-on-pay - Stock Titan |
| 2026-04-03 | +0.1% | news | Stock Titan | Stereotaxis (NYSE: STXS) files 10-K amendment adding EY consent - Stock Titan |